Current state of biomarker development for clinical application in epithelial ovarian cancer

This publication has 71 references indexed in Scilit:

• p53 autoantibodies, cytokine levels and ovarian carcinogenesis
  Gynecologic Oncology, 2009
• Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125
  Cancer Epidemiology, Biomarkers & Prevention, 2009
• Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
  British Journal of Cancer, 2009
• Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer
  PLOS ONE, 2009
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
  Published by Elsevier ,2009
• Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays
  Proceedings of the National Academy of Sciences, 2007
• Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
  Gynecologic Oncology, 2007
• Guidelines for Referral to a Gynecologic Oncologist: Rationale and Benefits
  Gynecologic Oncology, 2000
• Prospective Multicenter Study on CA 125 in Postmenopausal Pelvic Masses
  Gynecologic Oncology, 1994
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983